Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis

Q. Rehman, T. F. Lang, C. D. Arnaud, G. W. Modin, Nancy E Lane

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Daily treatment with hPTH (1-34) is associated with a significant increase in bone formation which results in large gains in lumbar spine bone mass. However, bone formation is known to occur on trabecular, endocortical and periosteal surfaces. The purpose of this study was to determine whether daily treatment with hPTH (1-34) for 1 year was associated with a change in vertebral cross-sectional area, or vertebral size, as measured by serial quantitative computed tomography scans. Fifty-one postmenopausal women treated chronically with both glucocorticoids and hormone replacement therapy (HRT) were randomized to either daily hPTH (1-34) for 1 year and HRT or to a control group treated with only HRT. Measurements of bone density of the spine were obtained every 6 months by dualenergy X-ray absorptiometry (DXA) and annually by QCT of the L1 and L2 vertebrae. Vertebral cross-sectional area (VCSA) was obtained from the QCT scans. In addition, we estimated the vertebral compressive strength (VSFOM, g2/cm4 = trabecular BMD2 x VCSA). After 1 year of hPTH (1-34) treatment, VCSA increased 4.8% (p < 0.001), and 1 year after treatment was discontinued VCSA was still 2.6% higher than the baseline value (p < 0.05). The control group had no change in VCSA. In addition, estimated vertebral compressive strength increased more than 200% over baseline levels in the hPTH (1-34) treatment group and no change was observed in the control group. In summary, daily treatment with hPTH (1-34) for 1 year increased vertebral size as measured by VCSA and this increase was maintained after hPTH (1-34) was discontinued. Since vertebral fracture risk is related to both bone size and bone mass, we cautiously speculate that the increase in vertebral size associated with hPTH (1-34) treatment is at least partially responsible for increased vertebral bone strength and reduction of fracture risk associated with this therapy in postmenopausal osteoporosis.

Original languageEnglish (US)
Pages (from-to)77-81
Number of pages5
JournalOsteoporosis International
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Teriparatide
Parathyroid Hormone
Glucocorticoids
Osteoporosis
Hormone Replacement Therapy
Compressive Strength
Spine
Therapeutics
Osteogenesis
Bone and Bones
Control Groups
Fracture Fixation
Postmenopausal Osteoporosis
Photon Absorptiometry
Risk Reduction Behavior
Bone Density
Tomography

Keywords

  • Bone size
  • PTH
  • QCT
  • Vertebra

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis. / Rehman, Q.; Lang, T. F.; Arnaud, C. D.; Modin, G. W.; Lane, Nancy E.

In: Osteoporosis International, Vol. 14, No. 1, 01.01.2003, p. 77-81.

Research output: Contribution to journalArticle

@article{b7cb9a2232fd439686e2f867cb43f48e,
title = "Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis",
abstract = "Daily treatment with hPTH (1-34) is associated with a significant increase in bone formation which results in large gains in lumbar spine bone mass. However, bone formation is known to occur on trabecular, endocortical and periosteal surfaces. The purpose of this study was to determine whether daily treatment with hPTH (1-34) for 1 year was associated with a change in vertebral cross-sectional area, or vertebral size, as measured by serial quantitative computed tomography scans. Fifty-one postmenopausal women treated chronically with both glucocorticoids and hormone replacement therapy (HRT) were randomized to either daily hPTH (1-34) for 1 year and HRT or to a control group treated with only HRT. Measurements of bone density of the spine were obtained every 6 months by dualenergy X-ray absorptiometry (DXA) and annually by QCT of the L1 and L2 vertebrae. Vertebral cross-sectional area (VCSA) was obtained from the QCT scans. In addition, we estimated the vertebral compressive strength (VSFOM, g2/cm4 = trabecular BMD2 x VCSA). After 1 year of hPTH (1-34) treatment, VCSA increased 4.8{\%} (p < 0.001), and 1 year after treatment was discontinued VCSA was still 2.6{\%} higher than the baseline value (p < 0.05). The control group had no change in VCSA. In addition, estimated vertebral compressive strength increased more than 200{\%} over baseline levels in the hPTH (1-34) treatment group and no change was observed in the control group. In summary, daily treatment with hPTH (1-34) for 1 year increased vertebral size as measured by VCSA and this increase was maintained after hPTH (1-34) was discontinued. Since vertebral fracture risk is related to both bone size and bone mass, we cautiously speculate that the increase in vertebral size associated with hPTH (1-34) treatment is at least partially responsible for increased vertebral bone strength and reduction of fracture risk associated with this therapy in postmenopausal osteoporosis.",
keywords = "Bone size, PTH, QCT, Vertebra",
author = "Q. Rehman and Lang, {T. F.} and Arnaud, {C. D.} and Modin, {G. W.} and Lane, {Nancy E}",
year = "2003",
month = "1",
day = "1",
doi = "10.1007/s00198-002-1312-0",
language = "English (US)",
volume = "14",
pages = "77--81",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "1",

}

TY - JOUR

T1 - Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis

AU - Rehman, Q.

AU - Lang, T. F.

AU - Arnaud, C. D.

AU - Modin, G. W.

AU - Lane, Nancy E

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Daily treatment with hPTH (1-34) is associated with a significant increase in bone formation which results in large gains in lumbar spine bone mass. However, bone formation is known to occur on trabecular, endocortical and periosteal surfaces. The purpose of this study was to determine whether daily treatment with hPTH (1-34) for 1 year was associated with a change in vertebral cross-sectional area, or vertebral size, as measured by serial quantitative computed tomography scans. Fifty-one postmenopausal women treated chronically with both glucocorticoids and hormone replacement therapy (HRT) were randomized to either daily hPTH (1-34) for 1 year and HRT or to a control group treated with only HRT. Measurements of bone density of the spine were obtained every 6 months by dualenergy X-ray absorptiometry (DXA) and annually by QCT of the L1 and L2 vertebrae. Vertebral cross-sectional area (VCSA) was obtained from the QCT scans. In addition, we estimated the vertebral compressive strength (VSFOM, g2/cm4 = trabecular BMD2 x VCSA). After 1 year of hPTH (1-34) treatment, VCSA increased 4.8% (p < 0.001), and 1 year after treatment was discontinued VCSA was still 2.6% higher than the baseline value (p < 0.05). The control group had no change in VCSA. In addition, estimated vertebral compressive strength increased more than 200% over baseline levels in the hPTH (1-34) treatment group and no change was observed in the control group. In summary, daily treatment with hPTH (1-34) for 1 year increased vertebral size as measured by VCSA and this increase was maintained after hPTH (1-34) was discontinued. Since vertebral fracture risk is related to both bone size and bone mass, we cautiously speculate that the increase in vertebral size associated with hPTH (1-34) treatment is at least partially responsible for increased vertebral bone strength and reduction of fracture risk associated with this therapy in postmenopausal osteoporosis.

AB - Daily treatment with hPTH (1-34) is associated with a significant increase in bone formation which results in large gains in lumbar spine bone mass. However, bone formation is known to occur on trabecular, endocortical and periosteal surfaces. The purpose of this study was to determine whether daily treatment with hPTH (1-34) for 1 year was associated with a change in vertebral cross-sectional area, or vertebral size, as measured by serial quantitative computed tomography scans. Fifty-one postmenopausal women treated chronically with both glucocorticoids and hormone replacement therapy (HRT) were randomized to either daily hPTH (1-34) for 1 year and HRT or to a control group treated with only HRT. Measurements of bone density of the spine were obtained every 6 months by dualenergy X-ray absorptiometry (DXA) and annually by QCT of the L1 and L2 vertebrae. Vertebral cross-sectional area (VCSA) was obtained from the QCT scans. In addition, we estimated the vertebral compressive strength (VSFOM, g2/cm4 = trabecular BMD2 x VCSA). After 1 year of hPTH (1-34) treatment, VCSA increased 4.8% (p < 0.001), and 1 year after treatment was discontinued VCSA was still 2.6% higher than the baseline value (p < 0.05). The control group had no change in VCSA. In addition, estimated vertebral compressive strength increased more than 200% over baseline levels in the hPTH (1-34) treatment group and no change was observed in the control group. In summary, daily treatment with hPTH (1-34) for 1 year increased vertebral size as measured by VCSA and this increase was maintained after hPTH (1-34) was discontinued. Since vertebral fracture risk is related to both bone size and bone mass, we cautiously speculate that the increase in vertebral size associated with hPTH (1-34) treatment is at least partially responsible for increased vertebral bone strength and reduction of fracture risk associated with this therapy in postmenopausal osteoporosis.

KW - Bone size

KW - PTH

KW - QCT

KW - Vertebra

UR - http://www.scopus.com/inward/record.url?scp=0037288854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037288854&partnerID=8YFLogxK

U2 - 10.1007/s00198-002-1312-0

DO - 10.1007/s00198-002-1312-0

M3 - Article

C2 - 12577188

AN - SCOPUS:0037288854

VL - 14

SP - 77

EP - 81

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 1

ER -